UNCY
NASDAQ · Biotechnology
Unicycive Therapeutics Inc
$4.64
-0.06 (-1.17%)
Open$4.66
Previous Close$4.70
Day High$4.68
Day Low$4.53
52W High$8.74
52W Low$3.71
Volume—
Avg Volume861.1K
Market Cap130.78M
P/E Ratio—
EPS$-1.62
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+35.1% upside
Current
$4.64
$4.64
Target
$6.27
$6.27
$3.63
$6.27 avg
$7.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 52.90M | 51.72M | 45.87M |
| Net Income | -11,930,457 | -10,903,389 | -10,566,816 |
| Profit Margin | -22.6% | -21.1% | -23.0% |
| EBITDA | -19,602,786 | -19,995,313 | -16,713,067 |
| Free Cash Flow | -9,449,797 | -9,177,412 | -10,735,832 |
| Rev Growth | -5.2% | +18.0% | +24.4% |
| Debt/Equity | 0.52 | 0.63 | 0.70 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.35 | -1.10% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $419.87 | +0.42% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $150.65 | -1.02% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $525.69 | -0.38% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | +0.00% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $252.46 | -1.14% | 41.4 | 33.44B |